Garraud Olivier
EA3064, Faculty of Medicine of Saint-Etienne, University of Lyon, Saint-Etienne, France; Institut National de la Transfusion Sanguine, Paris, France.
Transfus Apher Sci. 2017 Dec;56(6):920-923. doi: 10.1016/j.transci.2017.11.023. Epub 2017 Nov 8.
Contrary to what is generally considered, plasma for direct therapeutic use is all but "standard" and can be made using a multitude of variable processes differing from one preparation to another; in sum, those changes make the final component inhomogeneous especially within inter-blood bank comparisons. The variability is further multiplied by the donors' genetic polymorphisms. This is rarely addressed in the clinical trials and meta analyses, though this may have impact on clinical outcome in patients. This short review encompasses the variability parameters in the processing of therapeutic plasma and advocates for novel, prospective, trials to assess which type of plasma is the most beneficial to patients in need, as this type may differ depending on the patients' pathological condition.
与普遍认知相反，直接用于治疗的血浆远非“标准”血浆，其制备可采用多种不同的可变工艺，不同制剂之间存在差异；总之，这些差异使得最终成分不均匀，尤其是在不同血库之间的比较中。供体的基因多态性进一步加剧了这种变异性。尽管这可能会对患者的临床结局产生影响，但在临床试验和荟萃分析中很少涉及这一点。这篇简短的综述涵盖了治疗性血浆处理中的变异性参数，并主张开展新的前瞻性试验，以评估哪种类型的血浆对有需要的患者最有益，因为最佳血浆类型可能因患者的病理状况而异。
